IgY-technology (egg yolk antibodies) in human medicine: A review of patents and clinical trials

Leiva, Carlos Leónidas; Gallardo, M.; Casanova, Natalia A.; Terzolo, Horacio Raúl; Chacana, Pablo

doi:10.1016/j.intimp.2020.106269

Cited by 64 publications

(81 citation statements)

References 77 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In a scenario where vaccination against COVID- 19 is not yet available to everyone or does not yet offer adequate safety guarantees, the search for other prophylactic treatments becomes necessary. Many prophylactic treatments, including the desirable vaccines, are based on the development of host antibodies since they are proteins with high specificity and capable of neutralizing the virus or helping to eliminate it [104,105]. Currently, more than a hundred projects are being developed to achieve a COVID-19 vaccine [106,107], although the WHO warns that this may never come.…”

Section: Discussionmentioning

confidence: 99%

Can Immunization of Hens Provide Oral-Based Therapeutics against COVID-19?

et al. 2020

View full text Add to dashboard Cite

In the current worldwide pandemic situation caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and the newest coronavirus disease (COVID-19), therapeutics and prophylactics are urgently needed for a large population. Some of the prophylaxis strategies are based on the development of antibodies targeting viral proteins. IgY antibodies are a type of immunoglobulin present in birds, amphibians, and reptiles. They are usually obtained from egg yolk of hyper-immunized hens and represent a relatively inexpensive source of antibodies. Specific IgY can be produced by immunizing chickens with the target antigen and then purifying from the egg yolk. Chicken IgY has been widely explored as a clinical anti-infective material for prophylaxis, preventive medicine, and therapy of infectious diseases. Administered non-systemically, IgY antibodies are safe and effective drugs. Moreover, passive immunization with avian antibodies could become an effective alternative therapy, as these can be obtained relatively simply, cost-efficiently, and produced on a large scale. Here, we highlight the potential use of polyclonal avian IgY antibodies as an oral prophylactic treatment for respiratory viral diseases, such as COVID-19, for which no vaccine is yet available.

show abstract

Section: Discussionmentioning

confidence: 99%

Can Immunization of Hens Provide Oral-Based Therapeutics against COVID-19?

et al. 2020

View full text Add to dashboard Cite

show abstract

“…In this study, the kinetic parameters of hFcγRn to quail IgY were also determined. Numerous studies addressed IgY [ 37 , 38 , 39 , 40 ], because IgY is closer to the functional characteristics of IgG [ 37 ], and the research cost of IgY antibody is low, while the damage to animals is small [ 38 , 39 ]. However, there are few studies on the transfer of IgY through hFcγRn to the body and its immunoprotection.…”

Section: Discussionmentioning

confidence: 99%

Study on FcγRn Electrochemical Receptor Sensor and Its Kinetics

Peng

Pang

2020

Molecules

View full text Add to dashboard Cite

Neonatal γ-immunoglobulin (IgG) Fc receptor (FcγRn) is a receptor that transports IgG across the intestinal mucosa, placenta, and mammary gland, ensuring the balance of IgG and albumin in the body. These functions of FcγRn depend on the intracellular signal transduction and activation caused by the combination of its extracellular domain and IgG Fc domain. Nevertheless, there are still no kinetic studies on this interaction. Consequently, in the present study, we successfully constructed the human FcγRn (hFcγRn) electrochemical receptor sensor. The signal amplification system formed by chitosan nanogold-hFcγRn protein and horseradish peroxidase was used to simulate the cell signal amplification system in vivo, and the kinetic effects between seven IgG and hFcγRn receptors from different species were quantitatively measured. The results showed that the interaction of these seven IgGs with hFcγRn was similar to the catalytic kinetics of enzyme and substrate, and there was a ligand-receptor saturation effect. The order of the interconnect allosteric constants (Ka), which is similar to the Michaelis constant (Km), was human IgG < bovine IgG < horse IgG < rabbit IgG < sheep IgG < donkey IgG < quail IgY. The results showed that hFcγRn had the strongest ability to transport human IgG, which was consistent with the evolution of the system. Therefore, our hFcγRn electrochemical receptor sensor can be used to measure and evaluate the interconnected allosteric network. It is also an essential parameter of the interaction between hFcγRn and different IgGs and, thus, provides a new detection and evaluation method for immunoemulsion, therapeutic monoclonal antibody therapy, heteroantibody treatment, and half-life research.

show abstract

“…Importantly, it is easy to achieve high concentration (about 100 mg/egg) and high titer of IgY with appropriate immunization methods [ 10 ]. In contrast to other animal-produced antibodies, the production of IgY is much less painful for animals [ 11 ]. In addition, comparing with antibiotics, IgY is environmentally friendly without undesirable side effects, disease resistance, or toxic residues.…”

Section: Introductionmentioning

confidence: 99%

Production and characteristics of a novel chicken egg yolk antibody (IgY) against periodontitis-associated pathogens

et al. 2020

Journal of Oral Microbiology

View full text Add to dashboard Cite

Periodontitis is a bacterial biofilm-induced oral disease, mostly caused by Aggregatibacter actinomycetemcomitans ( A. actinomycetemcomitans ) and Porphyromonas gingivalis ( P. gingivalis ). Oral administration of chicken egg yolk antibody (IgY) is a promising nutritional strategy to control pathogen infections. The objective of this study was to produce an A. actinomycetemcomitans - and P. gingivalis -specific IgY and evaluate its effects on bacterial agglutination and biofilm formation. Thirty laying hens were immunized with a complex of lysate containing typical molecular weights of membrane proteins of A. actinomycetemcomitans and P. gingivalis . IgY was isolated by polyethylene glycol 6000 and ammonium sulfate and purified by dialysis. The results of enzyme-linked immunosorbent assay showed that the obtained IgY were specific to both A. actinomycetemcomitans and P. gingivalis . In addition, immunoelectron microscopy scanning and crystal violet staining showed that the IgY could bind to cell wall of the pathogens and efficiently accelerate agglutination and inhibit biofilm formation. Furthermore, the activity of the IgY remained stable at different temperature, pH, and storage period. This is the first report that a novel two-in-one IgY was produced to modulate the agglutination and biofilm formation of A. actinomycetemcomitans and P. gingivalis , suggesting the potential of IgY to control periodontitis caused by oral pathogens.

show abstract

IgY-technology (egg yolk antibodies) in human medicine: A review of patents and clinical trials

Cited by 64 publications

References 77 publications

Can Immunization of Hens Provide Oral-Based Therapeutics against COVID-19?

Can Immunization of Hens Provide Oral-Based Therapeutics against COVID-19?

Study on FcγRn Electrochemical Receptor Sensor and Its Kinetics

Production and characteristics of a novel chicken egg yolk antibody (IgY) against periodontitis-associated pathogens

Contact Info

Product

Resources

About